LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

It's also important that a brand is transparent about how they implement ... a cat needs varies based on age and activity level. The Merck Veterinary Manual says kittens should be given multiple ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

Merck (MRK) is down -10.1%, or -$10.10 to $89.69. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended ...

Gardasil, which prevents cancers caused by the human papillomavirus, has been one of Merck's top growth drivers aside from Keytruda, and much of its international growth had come from China before ...

Citi lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. The company’s Q4 was solid but the ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey · Reuters Michael Erman and Mariam Sunny Updated Tue, Feb 4, 2025, 7:21 AM 3 min read ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still ...